Prestige Consumer Healthcare
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
52% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 27
12% more capital invested
Capital invested by funds: $3.67B [Q3] → $4.09B (+$430M) [Q4]
3.65% more ownership
Funds ownership: 102.5% [Q3] → 106.16% (+3.65%) [Q4]
2% more funds holding
Funds holding: 323 [Q3] → 331 (+8) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 122 | Existing positions reduced: 112
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$93
8%
upside
Avg. target
$99
15%
upside
High target
$104
21%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
RBC Capital | 13%upside $97 | Sector Perform Maintained | 21 Mar 2025 |
Oppenheimer Rupesh Parikh 39% 1-year accuracy 11 / 28 met price target | 8%upside $93 | Outperform Maintained | 13 Feb 2025 |
Canaccord Genuity Susan Anderson 26% 1-year accuracy 10 / 38 met price target | 17%upside $100 | Buy Maintained | 7 Feb 2025 |
DA Davidson Linda Bolton Weiser 23% 1-year accuracy 24 / 105 met price target | 21%upside $104 | Buy Maintained | 7 Feb 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
5 days ago
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
Positive
Zacks Investment Research
1 week ago
Should You Consider Retaining PBH Stock in Your Portfolio Now?
Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.
Positive
Zacks Investment Research
1 month ago
PBH or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
Zacks Investment Research
1 month ago
PBH Q3 Earnings Beat Estimates, EPS View Raised, Shares Gain 14.8%
Prestige Consumer Healthcare witnesses continued international growth in the third quarter, banking on strong sales of the Hydralyte brand.
Neutral
Seeking Alpha
1 month ago
Prestige Consumer Healthcare Inc. (PBH) Q3 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q3 2025 Results Conference Call February 6, 2025 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Company Susan Anderson - Canaccord Genuity Keith Devas - Jefferies David Shakno - William Blair Linda Bolton Weiser - D. A. Davidson Anthony Lebiedzinski - Sidoti & Company Operator Thank you for standing by, and welcome to Prestige Consumer Healthcare's Third Quarter 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
1 month ago
Prestige Consumer Healthcare (PBH) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Prestige Consumer Healthcare (PBH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
1 month ago
Prestige Consumer Healthcare (PBH) Q3 Earnings and Revenues Beat Estimates
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.06 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook
TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024.
Neutral
Zacks Investment Research
1 month ago
PBH vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Zacks Investment Research
2 months ago
Prestige Consumer Stock Up 29.9% in a Year: What's Behind the Surge?
PBH sees remarkable gains from long-term brand-building strategies and developing the e-commerce channel.
Charts implemented using Lightweight Charts™